We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Holographic Imaging-Based COVID-19 Test Could Detect Both SARS-CoV-2 Infection and Antibodies in 30 Minutes

By LabMedica International staff writers
Posted on 14 Oct 2020
A new method using holographic imaging to detect both viruses and antibodies has the potential to aid in medical diagnoses and, specifically, those related to the COVID-19 pandemic. More...


The team of New York University (New York, NY, USA) scientists who have developed the new method base their test on holographic video microscopy, which uses laser beams to record holograms of their test beads. If fully realized, the proposed test could be done in under 30 minutes, is highly accurate, and can be performed by minimally trained personnel. Moreover, the method can test for either the virus (current infection) or antibodies (immunity).

The surfaces of the beads are activated with biochemical binding sites that attract either antibodies or virus particles, depending on the intended test. Binding antibodies or viruses causes the beads to grow by a few billionths of a meter, which the NYU researchers have shown they can detect through changes in the beads’ holograms.

“Our approach is based on physical principles that have not previously been used for diagnostic testing,” said David Grier, a professor of physics at NYU and one of the researchers on the project. “We can detect antibodies and viruses by literally watching them stick to specially prepared test beads.”

“We can analyze a dozen beads per second,” explained Grier, “which means that we can cut the time for a reliable thousand-bead diagnostic test to 20 minutes. And we can measure those changes rapidly, reliably, and inexpensively.”

The holographic video microscopy is performed by an instrument named xSight.
“This instrument can count virus particles dispersed in patients’ saliva and also detect and differentiate antibodies dissolved in their blood,” added Grier. “This flexibility is achieved by changing the composition of the test beads to model what we are testing.

“Each type of bead tests for the presence of a particular target, but can also test for several targets simultaneously. Our holographic analysis distinguishes the different test beads by their size and by their refractive index—an easily controlled optical property.”

The scientists say that this capability can be used to develop libraries of test beads that may be combined into test kits for mixing with patient samples. This will support doctors in distinguishing among possible diagnoses, speeding patients’ treatment, reducing the risk of misdiagnosis, and cutting the cost of healthcare.

Related Links:
New York University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.